"Our data suggest that once a patient is identified to be at risk of having an adverse event on the basis of traditional clinical, biochemical, and biomarker risk profiles, imaging may help identify those at greater risk of acute coronary events," write lead investigator Dr Sadako Motoyama (Fujita Health University School of Medicine, Toyoake, Japan) and colleagues in the June 30, 2009 issue of the Journal of the American College of Cardiology.
Speaking with heartwire , Dr Renu Virmani (Cardiovascular Pathology Institute, Gaithersburg, MD), one of the study investigators, said the results show for the first time that high-risk, vulnerable lesions, characterized previously in pathologic studies, are able to identify patients with future symptoms, and this moves the field forward by a "big step."
"This is just the beginning, but it is a good beginning," she said. "It is the first study we have showing us that we can actually identify these lesions and that these are the lesions that are going to produce symptoms in patients. Before that, it's all been a theory. We were able to say these are vulnerable plaques, and we should watch and worry about them, but we had no way of showing these were the ones that would go on to produce symptoms."
More Than 1000 Patients Assessed by CTA
To determine whether the characteristics of atherosclerotic lesions were associated with future acute coronary syndromes, the researchers analyzed the lesions based on the presence of positive vessel remodeling and low-attenuation plaques. Virmani explained that these two characteristics, along with a necrotic core, are thought to be associated with subsequent plaque rupture.
Among the 1059 patients who underwent CT angiography, 45 patients had coronary plaques that had undergone positive remodeling and were classified as low attenuation. After more than two years of follow-up, 10 patients, 22.2%, with both characteristics of vulnerable plaque developed an acute coronary syndrome. On the other hand, just one of the 27 patients with only one feature, either low attenuation or positive remodeling, developed symptoms, while only 0.5% of the 820 patients without any features of vulnerable plaque developed an acute coronary syndrome.
In a multivariable regression analysis, the presence of low-attenuation plaque or positive remodeling was associated with a 23-fold increase in the risk of an acute coronary syndrome (hazard ratio 22.8; 95% CI 6.9-75.2; p<0.001).
Virmani told heartwire that it is not always easy to identify low-attenuation plaque and that there are those who doubt whether visualizing these softer plaques can be done reliably, although the technology is improving. On the horizon are better imaging modalities, including 320-detector-row CT scanners that improve resolution, as well as machines that limit the amount of radiation exposure.
Systemic vs Focal Disease
Commenting on the results of the study for heartwire , Dr Steven Nissen (Cleveland Clinic, OH) said he was skeptical of the results and the vulnerable-plaque hypothesis, in general. In a recent editorial in the Journal of the American College of Cardiology: Cardiovascular Imaging, Nissen said that many diagnostic techniques designed to detect vulnerable plaques, including thermography, virtual histology, and optical coherence tomography, among others, have promised much but delivered little [2].
Last week, noted Nissen, a CT-angiography study, reported by heartwire , showed that the technology was unable to reliably identify the functional significance of coronary lesions in patients with stable angina and atypical chest pain. To now suggest that CT angiography can identify plaques at risk for rupture is "asking an awful lot from this technology." Also, he said the investigators did not show that the lesion of the coronary artery identified by CT angiography as vulnerable is responsible for the acute coronary syndrome.
"They don't close the loop," said Nissen. "We don't find out that the site that had positive remodeling and low attenuation is the site where the plaque ruptured. Without that, this becomes much more speculative."
In general, Nissen said that he believes the vulnerable-plaque approach is the wrong approach because atherosclerosis is a systemic disease, and if anything is likely to predict outcomes, it's a systemic, not focal, marker. Virmani, on the other hand, strenuously disagrees, telling heartwire that Nissen is "missing the boat" regarding these high-risk focal lesions because evidence shows that patients with coronary events have a focal thrombus formation.
"If you look at acute-myocardial-infarction patients, it occurs in one vessel, in the proximal areas," said Virmani. "Why? Those are the most prone areas. That's where we need to concentrate. His [Nissen's] idea of concentrating on systemic factors, such as LDL cholesterol, diabetes--yes, absolutely, but those are the patients that then have focal lesions. I don't deny that you need hypercholesterolemia for a patient to have focal lesions, but in the patients that are high risk, they do develop them at focal spots."
Did Anybody See My Stolen Horse?
In an editorial accompanying the published study, Dr Eugene Braunwald (Harvard Medical School, Boston, MA) adopts the middle road, hailing the study by Motoyama and colleagues as a landmark trial, while acknowledging the current limitations in the detection of vulnerable plaque [3].
Braunwald notes that widespread clinical application of CT angiography to characterize coronary lesions at risk for future rupture, which he aptly describes as "locking the barn before the horse is stolen," will require more potent measures for the prevention of plaque rupture than are currently available. Dual antiplatelet therapy, possible stenting, or more potent anti-inflammatory drugs are just some of the possibilities, writes Braunwald.
"Nobody is saying we need to start treating these patients," adds Virmani. "Start treating them systemically, just as Dr Braunwald points out in his editorial. Right now, we don't know how to treat these patients. We might need to think of different therapies. Some patients might need anti-inflammatory drugs, or some might need stents, but we won't know until we learn how these lesions behave prospectively."
Dr Mario Garcia (Mount Sinai School of Medicine, New York) told heartwire that low-attenuation plaques with positive remodeling are features identified as characteristics of thin-cap, lipid-rich plaques in intravascular ultrasound (IVUS) correlative studies. He added that while the present study identifies a novel imaging biomarker as a powerful predictor of future ACS, there remain unanswered questions, particularly whether the predictive accuracy of CT is superior to established serum biomarkers such as high-sensitivity C-reactive protein (CRP) and whether the same predictive utility could be extrapolated to asymptomatic subjects at risk.
In addition, like Braunwald and Nissen, Garcia says trials are needed to determine the optimal treatment strategy to follow--for example, intensive medical therapy vs prophylactic PCI--once these "high-risk features" are identified in a patient.
Source : http://www.medscape.com/viewarticle/705017?sssdmh=dm1.492501&src=nldne
No comments:
Post a Comment